MUT CRC cell lines significantly decreased cell proliferation and invasion. In addition, increased COL1A1 expression in CRC was significantly associated with serosal invasion, lymph metastases and hematogenous metastases. Taken together, the findings of the present study indicated that COL1A1 may serve as a candidate diagnostic biomarker and a promising therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) is the third most common cancer type and the fourth leading cause of cancer-associated mortality worldwide (1) . In 2012, there were ~1.36 million cases and 0.7 million mortalities worldwide (2) . CRC may be staged according to the American Joint Committee of Cancer tumor node metastasis or Dukes staging system (3, 4) . Dukes A/B and UICC I/II are considered early-stage CRC, Dukes C/D and UICC III/IV are considered late-stage CRC (5) . Surgical removal is the optimal treatment choice for CRC when detected early, but is often diagnosed too late, whereby the only feasible treatment option left is drugs. Cetuximab and bevacizumab exhibit therapeutic effects on CRC, but the treatment mechanisms are different. Cetuximab is an epidermal growth factor receptor (EGFR) monoclonal antibody and bevacizumab is a vascular endothelial growth factor receptor (VEGFR) monoclonal antibody. Clinically, EGFR monoclonal antibodies are considered if the VEGRF expression level of the patient is low. Thus, the present study focused on EGFR-targeted therapy in CRC (6, 7) . It has been reported that EGFR-targeted drugs exhibit a positive effect on KRAS proto-oncogene GTPase (KRAS) wild-type (KRAS WT ) CRC, but are ineffective on KRAS mutation (KRAS MUT ) CRC (8) . The Food and Drug Administration (FDA) have approved two monoclonal antibodies (cetuximab and panitumumab) that inhibit EGFR. Cetuximab is a chimeric IgGl anti-EGFR monoclonal antibody, while panitumumab is a complete human IgG2 anti-EGFR COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS monoclonal antibody (9) . Cetuximab and panitumumab have been demonstrated to increase the overall survival rate of CRC; however, cetuximab is <30% effective in patients (10) . Clinical data has confirmed that KRAS mutations reduce the effect of cetuximab and panitumumab, resulting in the use of these monoclonal antibodies only in patients with KRAS WT CRC (11) . Identifying drugs that are effective on KRAS WT and KRAS MUT CRC has significance for the treatment of patients with advanced CRC.
Bioinformatics is a field of study that uses computational methods to store, retrieve and analyze biological information. It is one of the newest fields of biological research (12) . Bioinformatics analysis involves the screening of large datasets from gene chips. There are a number of convenient online analytics tools (GEO2R, GCBI, DAVID, KEGG and GATHER) and analysis software (BRB-ArrayTools and Funrich) available. The present study aimed to investigate the common oncogenes of KRAS WT and KRAS MUT using bioinformatics analysis, and to perform gene function and pathway enrichment analysis. Additionally, the expression of COL1A1 in CRC tissues and cells was verified, and the association between COL1A1 and clinicopathological parameters in CRC clinical samples was analyzed.
KRAS mutation rates reached 40% in patients with CRC, as reported in 2017 (13) . Identifying target genes that are effective against wild-type and mutant KRAS may aid in identifying more effective drugs for the treatment of CRC, and provide a theoretical foundation for the application of relevant targets to clinical medicine.
Materials and methods
Microarray data. The gene expression profiles from the GSE38026 dataset were used for analysis in the presents study (https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE38026). GSE38026 was based on the Agilent GPL11532 platform (Affymetrix Human Gene 1. (14, 15) .
Identification of differentially expressed genes (DEGs).
Analysis was performed using GEO2R from the National Center for Biotechnology Information (16 Table I . RNA was reverse transcribed to cDNA using a PrimeScript Reverse Transcription kit (Takara Bio, Inc., Otsu, Japan). The RT reaction mixture contained 1 µl RNA (500 ng), 2 µl 5X PrimeScript Buffer, 0.5 µl PrimeScript RT enzyme mix I, 0.5 µl Oligo(dT) primer (50 µM), 0.5 µl random hexamers (100 µM) and 4.5 µl RNase-free ddH 2 O. The tubes were incubated for 37˚C for 15 min, followed by 85˚C for 5 sec, and then stored at 4˚C in the PCR instrument. qPCR analysis was performed using SYBR-Green I (Takara Bio, Inc.) and each experiment was performed in triplicate. The qPCR reaction mixture contained 10 µl SYBR-Green mix, 0.8 µl forward primer (10 µM), 0.8 µl reverse primer (10 µM), 1 µl cDNA and 7.4 µl RNase/DNase free ddH 2 O. The mixture was centrifuged (4˚C, 1,000 x g, 10 sec) and then placed in an ABI 7500 fluorescence quantitative PCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). The procedures for the PCR reaction were as follows: Pre-denaturation at 95˚C for 1 min; denaturation at 95˚C for 15 sec; annealing at 60˚C for 15 sec; and extension at 72˚C for 34 sec. Following 40 cycles, the Cq value of each sample was measured. Results were normalized to the expression of GAPDH as previously described (21) . The sequences of the COL1A1 primers were as follows: Forward, 5'-GAGGGCCAAGACGAAGACATC-3' and reverse, 5'-CAGATCACGTCATCGCACAAC-3'. The primers were obtained from PrimerBank (PrimerBank ID 110349771c1), with an amplicon size of 140 bp. The sequences of the GAPDH primers were as follows: Forward, 5'-GACTCATGACCACAGT CCATGC-3' and reverse, 5'-AGAGGCAGGGATGATGTT CTG-3' . The 2 -ΔΔCq method was used to calculate relative expression levels of COL1A1 in tissues. ΔCq was calculated as Cq(COL1A1)-Cq(GAPDH), and ΔΔCq was calculated as ΔCq(Tumor)-ΔCq(Control). As previously described, GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for graph construction (22) .
Tissue microarrays and immunohistochemistry. Tissue microarrays were constructed and immunostaining was performed using a two-step protocol. The tissue microarray was purchased from Shanghai Outdo Biotech Co., Ltd. (catalog no. HCol-Ade150CS-01). Detailed clinicopathological data of the 75 patients is presented in Table II . The two-step immunohistochemical detection kit was purchased from Boster Biological Technology (catalog no. SV0002; Pleasanton, CA, USA). Experimental procedures were performed according to the manufacturer's protocols. COL1A1 expression was measured using the Q550IW Computerized Image system (Leica Microsystems, Ltd., Milton Keynes, UK). The images were viewed using Aperio-ImageScope 12.0 software (23) . The anti-human COL1A1 antibody was purchased from Abcam (anti-rabbit; 1:1,000; catalog no. ab34710; Cambridge, MA, USA). The COL1A1 index was calculated as the (number of COL1A1-positive cells/total number of cells) x100% (magnification, x200) as previously described (24) .
Immunohistochemistry score. The total COL1A1 immunostaining score was calculated as the sum of the percentage positivity of stained tumor cells and the staining intensity. The percentage positivity was scored 0-3: 0, <10%; 1, 10-30%; 2, 31-50%; and 3, >50%. The staining intensity was scored 0-3; 0, no staining; 1, weakly stained; 2, moderately stained; and 3, strongly stained. The percentage positivity of cells and staining intensity were decided in a double-blinded manner. Then, the score of COL1A1 expression was calculated as the percentage positivity score x staining intensity score, which ranged between 0 and 9. The final expression level of COL1A1 was defined as 'low' (0-4) and 'high' (5-9).
Western blotting. Total proteins were extracted from CRC cells. The cells were lysed in cold lysis buffer (60 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.25% SDS and 1% Tergitol-type NP-40) containing 10 mM NaF, 1 mM Na 3 VO 4 and complete protease inhibitor (Roche Diagnostics, Basel, Switzerland) for 30 min on ice, and were then centrifuged at 10,000 x g at 4˚C for 15 min as previously described (25) . A bicinchoninic acid protein assay was used to determine protein concentration. A total of 45 µg protein was separated on 10% SDS-PAGE, transferred onto nitrocellulose membranes and blocked with 5% skimmed milk. Subsequently, the membranes were incubated with the anti-COL1A1 primary antibody (anti-rabbit; dilution 1:500; catalog no. ab34710) overnight at 4˚C. The next day, membranes were incubated with the HRP-conjugated goat anti-rabbit secondary antibody (dilution 1:10,000; catalog no. AS014; ABclonal Biotech Co., Ltd., Woburn, MA, USA) as previously described (26) . Semiquantification of proteins was performed using a Tanon GIS gel imaging system (Tanon1600; Tanon, Shanghai, China) as previously described (27) .
Construction of a COL1A1 knockout cell line and transfection.
shRNA targeted against COL1A1 was purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China) with the following nucleotide sequence: 3'-TTGGTTTGCGATGACGTG-5'. The COL1A1 shRNA (2 µg) and shRNA GFP control plasmids were transfected with Lipofectamine 2000 (catalog no. 11668019; Invitrogen; Thermo Fisher Scientific, Inc.) as previously described (26) .
Cell counting kit-8 (CCK-8) assay.
The CCK-8 proliferation assay kit was purchased from Nanjing KeyGen Biotech Co., Ltd. (catalog no. KGA317, Nanjing, China). The cell proliferation assay was performed over 4 days every 24 h with 1x10 3 cells/well. CCK-8 reagent (10 µl) was added to each well, and then the plate was incubated for 2 h at 37˚C. After that, the absorbance was measured at 450 nm using a Vmax microplate spectrophotometer (Molecular Devices, LLC, Sunnyvale, CA, USA) as previously described (28) . All measurements were performed in quintuplicate in three separate experiments.
Cell invasion assay. Caco2 and SW480 cells were used for cell invasion assays. A Transwell filter was purchased from Corning Incorporated (Corning, NY, USA). The cells were digested with 0.25% trypsin and seeded into the Transwell upper chamber coated with Matrigel. RPMI-1640 culture medium was added to the upper chamber, while RPMI-1640 with FBS was plated into the lower chamber. After 24 h of culture, the Transwell chamber was removed. Following washing twice with PBS, the cells were fixed with 4% polyformaldehyde for 20 min at room temperature, washed twice with PBS and stained with Giemsa (10 µg/ml) for 20 min at room temperature. Cells that passed through the Matrigel and the micropores to the lower chamber were observed under a light microscope. Cells were counted under a light microscope (magnification, x200) and the invasion percentage was determined by dividing by the number of cells on the first day as previously described (29) .
Bioinformatics analysis of COL1A1 and NEK2 expression levels. COL1A1 and NEK2 expression was analyzed in CRC tissues compared with adjacent tissues based on the Oncomine microarray dataset (https://www.oncomine.org/resource/ login.html). The genes associated with NEK2 were calculated using GEPIA (http://gepia.cancer-pku.cn/index.html).
Statistical analysis. Data were analyzed using SPSS 20.0 statistical software (IBM Corp., Armonk, NY, USA). Quantitative data are presented as the mean ± standard deviation of at least three independent experiments. The differences between multiple groups were used analysis of variance followed by the Tukey's post hoc test, and two groups were examined using a two-tailed Student's t-test. Correlation analysis was determined using Pearson's correlation analysis. The associations between COL1A1 expression and clinicopathological characteristics were determined using the χ 2 test. P<0.05 was considered to indicate a statistically significant difference. P<0.05; P<0.01; P<0.001.
Results

Identification of DEGs common for KRAS
WT and KRAS MUT CRC. Paired KRAS WT cancer samples and adjacent control tissues were analyzed using GEO2R, which led to the identification of 395 upregulated DEGs. Similarly, eight paired KRAS MUT cancer samples and adjacent control tissues were analyzed, whereby 519 upregulated DEGs were identified. The intersection of DEGs included 294 common DEGs that were independent of the KRAS genotype (Fig. 1) .
GO and pathway analysis. Regarding biological processes, upregulated common DEGs exhibited enrichment for cell communication, signal transduction and cell growth ( Fig. 2A) . Cell component analysis revealed enrichment in cytoplasmic, extracellular and extracellular compartments (Fig. 2B) . Regarding molecular function, the DEGs were enriched in metallopeptidase activity, extracellular matrix structural constituents and receptor binding (Fig. 2C) . The pathway analysis revealed enhanced involvement in cell cycle, DNA replication and the WNT signaling pathway (Fig. 2D) .
Hub-protein screening from the PPI network. Based on data from the STRING database, the top three hub modules that satisfied the preset criteria (MCODE score >5 with the number of nodes >5), including TPX2 microtubule nucleation factor (TPX2), NIMA related kinase 2 (NEK2) and COL1A1, were identified using Cytoscape software analysis (Fig. 3) . The expression levels of COL1A1 were upregulated 2.1-fold, while NEK2 was increased 1.5-fold in cancer tissues compared to healthy tissues. Drugs targeting NEK2 (Drugbank ID, DB07180; https://www.drugbank. ca/drugs/DB07180) and COL1A1 were identified using Drugbank (Drugbank ID, DB04866; https://www.drugbank. ca/drugs/DB04866), while no drugs targeting TPX2 were identified. Only one type of drug that targets NEK2 was identified and it is in the experimental phase. There are four types of drugs that target COL1A1, but only halofuginone is associated with cancer therapy and is currently in the approval process. Halofuginone is able to inhibit matrix metalloproteinase (MMP) and cell proliferation, as well as inhibit tumor matrix support, vascularization, cell invasion and cell proliferation (30) . Therefore, COL1A1 and NEK2 may serve key roles in cancer development, and their target drugs may have important clinical application value.
COL1A1 mRNA is upregulated in CRC tissues and cells regardless of KRAS genotype.
COL1A1 was identified to be significantly upregulated in CRC tissues compared with adjacent tissues based on the Oncomine microarray dataset, which is a web-based data-mining platform (31) (Fig. 4A) . In the Oncomine database, all the CRC chip results were upregulated. Of the 11 upregulated microarray databases, The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov/) database was selected to further determine the expression patterns of COL1A1. TCGA is a powerful database platform for integration of multiple cancer genome sequencing data. This database included 19 colon specimens, three rectum specimens and 22 colorectal mucosa adenocarcinoma specimens. The results demonstrated that COL1A1 expression was upregulated 9.62-fold in CRC specimens compared with control colorectal tissue specimens. Additionally, the expression level of COL1A1 mRNA in tumor and non-tumor tissues from 24 patients with CRC was confirmed. RT-qPCR analysis revealed significantly higher COL1A1 mRNA expression in 20/24 CRC specimens compared with the adjacent control mucosa tissues (P<0.001; Fig. 4B and C) . The expression levels of COL1A1 mRNA were further evaluated in six KRAS WT and KRAS MUT CRC cell lines, LOVO, DLD-1, Caco2, HT29, SW620 and SW480. Compared with the control colorectal epithelium FHC cells, the expression levels of COL1A1 mRNA were significantly upregulated in all investigated CRC cell lines (Fig. 4D) .
COL1A1 protein is upregulated in CRC tissues and cells regardless of KRAS genotype.
The protein expression levels of COL1A1 in 75 paired CRC and adjacent control tissues were determined using tissue microarray. COL1A1 protein expression was significantly higher in CRC tissues compared with adjacent tissues (Fig. 5A and B) . Furthermore, in order to investigate the clinicopathological significance of COL1A1, the expression of COL1A1 was divided into a high-expression group (n=12) and a low-expression group (n=12) based on the median COL1A1 expression level, which was 5.191489802. It was demonstrated that COL1A1 expression was positively associated with serosal (Table III) . The expression of COL1A1 protein was also detected in CRC cell lines. The expression of COL1A1 protein was significantly upregulated in the investigated CRC cell lines compared with that in FHC cells, independent of KRAS status (Fig. 5C and D) . These results indicated that the expression of COL1A1 mRNA and protein in CRC cells was increased, regardless of whether KRAS was mutated or not. Therefore, COL1A1 may be effective as a drug target for KRASMU or KRAS WT CRC. WT and KRAS MUT CRC cell lines. Based on the obtained results, two CRC cells lines Caco2 (KRAS WT ) and SW480 (KRAS MUT ) were selected to explore the role of COL1A1 in cell proliferation and invasion. shRNA COL1A1 was used to inhibit the expression of the COL1A1 in the two cell lines and the efficiency of transfection was assessed by western blotting (Fig. 6A) . The cell proliferation assay demonstrated that inhibition of COL1A1 significantly decreased the proliferation of Caco2 and SW480 cells (Fig. 6B and C) . Proliferation decreased from the second day and was most notable on the fourth day in the two cell lines. Similarly, inhibition of COL1A1 significantly decreased the invasive abilities of Caco2 and SW480 cells by day 3 (Fig. 6D and E) .
Inhibition of COL1A1 suppresses proliferation and invasion in KRAS
Bioinformatics analysis of NEK2 expression level and function.
NEK2 was upregulated in CRC tissues compared with adjacent tissues based on the Oncomine microarray dataset. The results of the TCGA database analysis are presented in Fig. 7A . This database included 19 colon specimens, three rectum specimens and 101 colorectal mucosa adenocarcinoma specimens. The results demonstrated that NEK2 expression was upregulated 3.496-fold in CRC specimens compared with control colorectal tissue specimens. Furthermore, the results from the TCGA data revealed that NEK2 was significantly correlated with MYC proto-oncogene bHLH transcription factor (c-Myc), Cyclin D1, cluster of differentiation (CD) 44 and Snail genes, but not with MMP9 or MMP2 (Fig. 7B) . The data were calculated using GEPIA (http://gepia.cancer-pku.cn/ index.html) (Fig. 7) . These results suggested that NEK2 may serve a role in tumor proliferation and metastasis, but that it does not promote metastasis by dissolving matrix components.
Discussion
CRC is one of the most common types of malignancies, with >1.2 million patients being diagnosed with CRC and the number of mortalities exceeding 600,000 every year worldwide (32) . In the United States and other Western countries, the incidence of colorectal cancer ranks third among all malignant tumors, and the mortality rate in males and in females ranks second and third, respectively (1). Surgical treatment is primarily used at the early stages; however, ~80% of patients are diagnosed with colon cancer at the late stage (2) .
The FDA has approved cetuximab and panitumumab for the treatment of advanced CRC. These antibodies target human EGFR (33) . Initially, these targeted drugs were used in all patients with CRC, but it was later noted that only KRAS WT patients respond well to treatment, whereas in KRAS MUT patients the application of antibodies may be not only ineffective, but also harmful (7) . Since the proportion of KRAS MUT patients is ~40% (34) , it is important to explore novel drug targets for CRC.
In order to identify drugs targeting genes that are uniformly effective in KRAS WT and KRAS MUT CRC, bioinformatics techniques were used to analyze CRC samples from the GSE38026 gene expression dataset. A total of 294 commonly upregulated genes outside of the KRAS pathway were identified in the present study. These genes serve as a pool of potential uniformly effective therapy targets for CRC.
The results of GO and KEGG analyses demonstrated that the DEGs were enriched for genes involved in cell proliferation, signal transduction and tumor pathways. The PPI network analysis identified three core genes; TPX2, NEK2 and COL1A1. The expression levels of COL1A1 and NEK2 in CRC tissues were upregulated by 2.1-and 1.5-fold compared with healthy tissues, respectively. Drugbank was also searched, and drugs specifically targeting NEK2 and COL1A1 were identified (35) . The one drug targeting NEK2 is 5-[(Z)-(5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N,2,4-trimethyl-1H-pyrrole-3-carboxamide. This drug is currently being investigated; thus, its pharmacological effect remains unclear. There are four drugs targeting COL1A1, only the role of halofuginone has been associated with cancer treatment, and is currently in the approval process (36) . Halofuginone is an effective inhibitor of COL1A1 and MMP2 gene expression, and inhibits extracellular matrix deposition and cell proliferation (36) . The profound antitumor effects of halofuginone are attributed to its combined inhibition of tumor matrix support, vascularization, invasiveness and cell proliferation (36). COL1A1 is a major component of collagen type I, the literature associated with COL1A1 is primarily focused on osteogenesis, osteoporosis and bone diseases (37) . Previously, it has been demonstrated that the COL1A1 is deregulated in a variety of tumors, including breast and gastric cancer, and that the expression of COL1A1 is higher in tumor tissues and tumor cells compared with healthy control colon mucosa samples and intestinal mucosal epithelial FHC cells, respectively (38) (39) (40) (41) (42) (43) .
To further confirm the results observed through bioinformatics analysis in the present study, the protein and mRNA expression levels of COL1A1 in CRC and adjacent control tissues were analyzed using immunohistochemistry and RT-qPCR, respectively. The results confirmed that COL1A1 was significantly upregulated in CRC tissue compared with adjacent tissue. No significant association was identified between COL1A1 expression and age, sex or tumor size following analysis of the clinicopathological data of patients with CRC. However, the expression was significantly associated with serosal infiltration, lymph node metastasis and hematogenous metastasis. Furthermore, the effects of COL1A1 on the growth and invasion abilities of CRC cells were assessed. The results of the functional experiments demonstrated that COL1A1 knockdown significantly reduced the proliferation and invasiveness of Caco2 and SW480 cells. Based on the results of our previous study, COL1A1 was demonstrated to promote CRC cell migration in vitro (26) . Thus, we hypothesized that COL1A1 may be involved in the proliferation, invasion and metastasis of CRCs.
The drug target, NEK2, as a hub gene is also of interest. A previous study demonstrated that the combined treatment of NEK2 siRNA and cisplatin for CRC improved the antitumor effects of cisplatin (44) . siRNAs are not widely used in clinical treatment currently; thus, drugs targeting NEK2 may be more practical at present. The expression and co-expression of NEK2 was analyzed using an online web service, GEPIA. The results demonstrated that the expression levels of NEK2 were upregulated in CRC compared with control colorectal tissue specimens. Furthermore, NEK2 expression was significantly correlated with c-Myc, Cyclin D1, CD44 and Snail gene expression, but not with MMP2 and MMP9 expression. C-Myc and Cyclin D1 are associated with tumor proliferation, CD44 and MMP9 genes are associated with tumor metastasis, and Snail is associated with epithelial-mesenchymal transition. These results suggested that NEK2 may serve a role in CRC proliferation and metastasis, but may not promote metastasis by dissolving matrix components.
In conclusion, COL1A1 and NEK2 as therapeutic gene targets may result in improved therapeutic outcomes in KRAS WT and KRAS MUT patients with CRC.
